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Abstract
Background: Interaction of fibrinogen with specific leukocyte integrins of monocytes may link coagulation and
inflammation, however, the precise mechanism of fibrinogen leading to the pro-inflammatory and pro-coagulatory
response on monocytes is yet unknown.
Results: Fibrinogen and its digestion fragment D induced pro-coagulant activation of monocytes as assessed in a
cellular coagulation assay by reductions in clotting times. Pro-coagulant activation was reversed by blocking
antibodies against Mac-1 or LFA-1. Pre-exposure of monocytes to the p38 MAPK inhibitor SB 202190 and the
MEK1.2 inhibitor U0126 led to significant increasees in coagulation times whereas blocking JNKII with its inhibitor
had no such effect. Blocking NFB with MG-132 also inhibited pro-coagulant activation of monocytes by
fibrinogen. A selective inhibitor of matrix metalloproteinase-9 increased times to clot formation whereas other
matrix metalloproteinase inhibitors did not significantly interfere with fibrinogen-augmented clot formation in this
assay. Treatment of monocytes with fibrinogen increased concentrations of matrix metalloproteinase-9
immunoreactivity in their supernatants.
Conclusions: Fibrinogen induces monocyte pro-coagulant activation in an integrin-, nuclear factor B-, p38 MAPK-,
and MEK1.2-dependent manner. Activation of monocytes by fibrinogen increases metalloproteinase-9 secretion,
metalloproteinase-9 itself enhances monocyte coagulation by an autocrine mechanism. Results provide further
evidence that mediators of hemostasis have a profound impact on cells of the immune system and are closely
related to inflammatory pathways.
Background
Fibrinogen is a 45 nm long glycoprotein consisting of
three pairs of polypeptide chains, Aa,B b and g, symme-
trically interconnected through multiple disulfide bonds
forming a dimer. In addition to its well-known functions
in hemostasis, over the past two decades there has been
an increasing appreciation of the important function
that fibrinogen exerts in the innate immune system. Stu-
dies indicate that fibrinogen plays a multifaceted role in
inflammatory response, indicative of a close relationship
between hemostatic and inflammatory pathways [1-4].
Acute inflammatory events are known to shift the
hemostatic balance toward a pro-thrombotic state [5-7].
One established mechanism whereby inflammatory
mediators can promote coagulation is the enhanced
expression of tissue factor on endothelial cells and
monocytes [8,9].
The ability of fibrinogen to participate in the inflam-
matory response depends on its interaction with specific
leukocyte integrins [10-13]. The main fibrinogen recep-
tors on leukocytes are CD11b/CD18 (Mac-1, amb2)a n d
CD11c/CD18 (axb2). Leukocyte emigration from the
blood to the sites of inflammation is currently viewed as
an adhesion cascade that involves coordinated function
of a variety of adhesion receptors on leukocytes and
endothelial cells [14]. It has been shown that elevated
plasma fibrinogen and fibrinogen degradation products
(FgDP) inhibit several functions in neutrophils critical to
the bactericidal activity of inflammatory cells [12].
Furthermore it has been suggested that fibrinogen pro-
duction may be controlled by regulatory proteins
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fragments D and E [15]. Conceivably FgDPs could sti-
mulate monocytes to release interleukin-1, interleukin-6
and TNF-a[11]. Moreover fibrinogen acts as a bridging
ligand for the adhesion of monocytes to cultured
endothelial cells by the binding of a specific sequence of
its D-domain to ICAM-1 on endothelial cells [16,17].
The N-terminal disulfide knot binds to CD11b/CD18
and CD11c/CD18 (axb2) on stimulated neutrophils [18].
Monocytes play a key role in the orchestration of the
pro-inflammatory response. These cells migrate from
the peripheral blood into various tissues and differenti-
ate into macrophages. Cells of the mononuclear phago-
cytotic system have been linked to a variety of
inflammatory diseases, particularly to atherosclerosis,
where macrophages transform into foam cells and lead
to the plaque formation. Moreover, elevated fibrinogen
levels in young people were independently associated
with subclinical atherosclerosis [19]. Interaction of fibri-
nogen with specific leukocyte integrins of monocytes
may link coagulation and inflammation, however, the
precise mechanism of fibrinogen leading to the pro-
inflammatory and pro-coagulatory response on mono-
cytes is yet unknown.
Results
Pro-coagulant activation of monocytes by fibrinogen
In order to assess fibrinogen’s potential to form stable
monocyte conglomerates, coagulation assays were per-
formed. Clotting time of cells pre-incubated with either
lipopolysaccharide (LPS) or interleukin-1 (IL-1) was 60%
reduced compared to control (RPMI 1640-) treated cells
(Fig. 1; IL-1 data not shown). Treatment with fibrino-
gen, either Haemocomplettan® or control fibrinogen
(Haematological Technologies Inc.) reduced the clotting
time of monocytes. At its most potent concentration of
2 mg/mL, Haemocomplettan® and control fibrinogen
reduced the time for clot formation up to 60% and 45%,
respectively, compared to untreated cells.
As fibrinogen is usually digested into its fragments D
and E in vitro, we tested the effects of these fragments
on the coagulation time of human monocytes. Only
fragment D was able to induce clot formation, while
fragment E had no appreciable effect on clot formation
(Fig. 2).
Earlier reports have indicated that monocytes which
are pre-stimulated with TNF-a adhere to the E- fragment
whereas unstimulated monocytes only adhere to the D
fragment and the N-terminal disulfide knot [11]. How-
ever, different domains of the fibrinogen molecule seem
to interact with different integrins [11]. One possible
explanation for the difference in monocyte reactivity to
the different digestion products might be related to dif-
ferences in integrin expression on leukocytes [11].
Therefore coagulation experiments with blocking antibo-
dies directed against the most important leukocyte integ-
rins, LFA-1 and Mac-1, were performed. Interestingly,
blockade of both inegrins, LFA-1 and Mac-1, resulted in
prolonged coagulation times compared to fibrinogen-
only-treated cells. This observation was true for intact
fibrinogen molecules as well as the D-fragment (Fig. 3).
Blockade of integrins without fibrinogen exposure failed
to increase the time to clot formation (data not shown).
Usually, integrin-activation results in the activation of
the ERK/MAPK pathway [20]. To further assess the
importance of integrin signaling in the interaction of
fibrinogen with monocytes, we performed signal trans-
duction experiments with inhibitors of the ERK/MAPK
pathway. Inhibitors of p38 MAPK and MEK1/2 reversed
fibrinogen-induced clotting of monocytes whereas the
inhibition of JNKII had no effect on coagulation times
(Fig. 4). Furthermore, inhibition of NF-B delayed clot
formation, suggesting that pro-inflammatory pathway
activation might be required to increase the capacity of
monocytes to form aggregates.
Matrix metalloproteinase-9-mediated activation of
monocytes by fibrinogen
The major ligand-binding site within the a-chain of leu-
kocyte integrins is called inserted domain (I-domain)
and is homologous to the A domains of von Willebrand
factor [12]. Interestingly, matrix metalloproteinase-9
(MMP-9), the most abundant MMP produced by mono-
cytes, also binds to this I-domain of integrins and initi-
ates the adhesion process [13]. Therefore, we performed
cellular coagulation experiments in the presence of
MMP-inhibitors. Again, cells were activated by fibrino-
gen and co-treated with MMP-inhibitors. Pre-treatment
with a MMP-9 inhibitor completely reversed fibrinogen-
induced clot formation of monocytes, whereas multiple
other MMP inhibitors directed towards MMP-1, MMP-
3, MMP-8, and MMP-13, did not affect monocyte
aggregation (Fig. 5). Inhibition of various MMPs did not
influence the coagulation time of untreated monocytes
(data not shown).
Monocytes stimulated either by fibrinogen or other
pro-inflammatory mediators may exert an autocrine
mechanism of integrin activation by the further produc-
tion and release of MMP-9. Therefore release into the
supernatants of fibrinogen-activated monocytes of
MMP-9 and, as a control, MMP-1 was tested, as well as
were the intracellular levels of these MMPs measured.
There was no difference in MMP-1 levels after fibrino-
gen treatment (data not shown). However, extra-cellular
MMP-9 levels increased concentration-dependently up
to 15-fold as compared to supernatants of untreated
cells (Fig 6A). Intra-cellular MMP-9 levels showed a dif-
ferent pattern: upon stimulation with fibrinogen at the
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content dereased to lower levels as compared to stimu-
lation of cells with the lower concentration of 2 μg/mL
(Fig 6B). The reason for this phenomenon might be
enhanced secretion of the metalloproteinase in mono-
cytes with fibrinogen at higher concentrations. At lower
concentrations release into supernatants and de novo
production might be in steady state.
Discussion
In this investigation, we provide evidence that fibrino-
gen-induced clot formation of monocytes dependents on
Mac-1 and LFA-1 activation. Fibrinogen is thought to
bind to leukocyte integrins and causes leukocyte adher-
ence to the injured vessel wall. In this regard, recent
studies demonstrated that simultaneous fibrinogen bind-
ing to leukocytes and endothelial cells enhances adhe-
sion of monocytes to the endothelium by acting as a
molecular bridge between the two cell types [16,17,21].
Stimulation of integrins by specific agonists activates
and renders them competent to bind soluble fibrinogen,
while non-stimulated integrins, however, are able to
bind immobilized fibrinogen [12]. In our case no immo-
bilized fibrinogen was used but all experiments were
Figure 1 Pro-coagulant activation of human monocytes by fibrinogen. To test the ability of human fibrinogen to accelaerate monocyte
coagulation, cells were pre-exposed to Haemocomplettan®, a plasma-derived fibrinogen concentrate in clinical use, (left panel) or to a
commercially available fibrinogen from Haematological Technologies Inc (right panel). Both products led to a comparable inhibition of the
clotting time at concentrations as low as 2 mg/mL. As endotoxin is known to induce monocyte coagulation it served as positive control. PMCs
and monocytes were used for the left panel, monocytes were used in the experiments on the right panel. Normalized results are given as mean
± SEM, n = 6. Time to clot formation of control monocytes (RPMI 1640 treated) was 360 ± 46.7 sec. Statistics were calculated using Kruskal Wallis
and Mann Whitney U test. *: p < 0.05.
Figure 2 Pro-coagulant activation of human monocytes by fibrinogen fragments D and E. The biological activity of the fibrinogen
digestion fragments D and E were tested. Cells were pre-treated for 4 h under rotating conditions with fibrinogen fragments D or E (0.2 mg/
mL) and the procoagulant activity of monocytes was tested. Like the entire molecule, fragment D decreased coagulation time significantly to
65% of untreated control cells (348 ± 56.9 sec) whereas fragment E had only a non-significant effect on the formation of stable monocyte clots.
Results are given as mean ± SEM, n = 3.*: p < 0.05.
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fore it is very likely that mediators other than fibrinogen
led to the monocyte-monocyte adhesions observed in
the coagulation experiments .O u rd a t ai n d i c a t et h a t
fibrinogen initially activates pro-inflammatory pathways
s i n c eb l o c k a d eo fN f k Bp r o l o n g e dt h et i m ef o rc l o tf o r -
mation. It is known that fibrinogen does not only lead
to adhesion of monocytes, it also induces de novo
synthesis of IL-6 and TNF-a [1].
A strong candidate for a possible monocyte-monocyte
interaction via the integrin pathway was MMP-9. Inter-
estingly, only pharmacological inhibitors of MMP-9
increased coagulation time almost to baseline levels,
suggesting an important role of MMP-9 in this context.
Stimulation of monocytes with fibrinogen under rotation
led to a significant increase in intra- and extracellular
levels of the protease. However, MMP-9 not only binds
to integrins and induces adhesion, it might also augment
t h ep r o - i n f l a m m a t o r yr e s p o n s et of i b r i n o g e nv i aap o s i -
tive feedback loop.
In vitro studies have shown that fibrinogen may pro-
foundly alter leukocyte functions leading to increased
cell migration, phagocytosis, NfkB-mediated transcrip-
tion and other processes [10,22,23].
Conclusions
In vitro, fibrinogen induces monocyte pro-coagulant
activation in an NFB- and MMP-9-dependent manner
by specific ligation of signal-transducing integrins that
also induces TF expression in the cells. These results
provide further evidence that mediators of hemostasis
have a profound impact on cells of the immune system
and are closely related to inflammatory pathways in
which MMPs play a prominent regulatoy role.
Methods
Materials
Hanks balanced salt solution (HBSS) without Ca
2+ and
Mg
2+ was purchased from Gibco BRL, Life Technologies
(Vienna, Austria). Lymphoprep was from Nycomed
Pharma (Oslo, Norway), anti-human CD14 antibody was
from Miltenyi Biotec (Bergisch Gladbach, Germany),
Bovine serum albumin (BSA), was purchased from Dade-
Behring (Marburg, Germany). RPMI 1640 was purchased
from Biological Industries (Kibbutz Beit Haemek, Israel).
Fibrinogen was either from CSL Behring (Haemocomplet-
tan) or from Haematological Technologies Inc. (Essex
Figure 3 Effect of blocking antibodies against the major
leukocyte integrins on fibrinogen-triggered pro-coagulant
activation of human monocytes. Pre-treatment of human
monocytes in the additional presence of blocking antibodies against
Mac-1 or LFA-1 led to a sustainable prolongation of the coagulation
time compared to fibrinogen- or digestion fragment D-treated cells
alone; antibodies in the absence of fibrinogen or fibrinogen
fragment D did not alter coagulation times (data not shown).
Experiments were performed with the intact fibrinogen molecule.
Results are given as mean ± SEM, n = 3. Control: p < 0.05.
Figure 4 Inhibitors of the p38 MAPK and MEK1/2 pathway
block fibrinogen-triggered pro-coagulant activation of human
monocytes. As integrins primarly signal via p38 MAPK and MEK1/2
pathways, experiments with inhibitors against p38 MAPK, MEK 1/2
and JNKII were performed. Pre-exposure of the monocytes to the
p38 MAPK inhibitor SB 202190 and the MEK 1.2 inhibitor U0126 led
to a significant increase in coagulation time whereas blocking JNKII
with its inhibitor had no effect on coagulation. Activation of NFB
by certain stimuli switches monocytes from their resting state into
activated monocytes that transform into macrophages. Blocking
NFB with MG-132 inhibited the activation of monocytes by
fibrinogen, the pro-coagulant activity of MG-132-treated cells was
107% of un-treated control cells. Results are given as mean ± SEM,
n = 3.*: p < 0.05.
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obtained from Haematological Technologies Inc as well.
The E. coli LPS was from Sigma Aldrich. The signal trans-
duction inhibitors SB 202190, U0126, JNK Inhibitor II and
the NfkB MG-132 inhibitor were from Calbiochem
(Gibbstown, NJ) as were the MMP-inhibitors. MMP-
ELISA kits (proMMP-1 and MMP-9) and the blocking
integrin-antibodies were purchased from R&D systems
(Minneapolis, MN).
Preparation of human monocytes
Mononuclear cells were prepared from peripheral venous
blood (anticoagulated with EDTA) of healthy volunteers.
After Lymphoprep® density gradient centrifugation, per-
ipheral blood mononuclear cells were collected and
washed three times with normal saline. Positive selection
of monocytes was performed by adding MACS colloidal
superparamagnetic microbeads conjugated with mono-
clonal anti-human CD14 antibodies to cooled, freshly
prepared peripheral blood mononuclear cell preparations
in MACS buffer (PBS with 5 mM EDTA and 0.5% bovine
serum albumin) according to the manufacturer’s instruc-
tions. Cells and microbeads were incubated for 15 min at
4-6°C. In the meantime, the separation column was posi-
tioned in the MACS magnetic field and washed with
MACS buffer at room temperature. The cells were
washed with MACS buffer, resuspended, and loaded onto
the top of the separation column. The eluent containing
CD14
- cells was withdrawn and after removal of the col-
umn from the magnet, trapped monocytes (CD14
+)w e r e
eluted with the six-fold am o u n to fc o l dM A C Sb u f f e r ,
centrifuged, and resuspended in medium containing 0.5%
BSA.
Monocyte coagulation assay
Based on the concept that tissue factor bearing cells
localize and form the hemostatic plug, cell based models
of coagulation have been developed that mimic - at least
in part - in vivo coagulation reactions.
For the coagulation experiments, monocytes were
incubated with the particular reagent for 4 h under con-
tinuous rotation to prevent monocyte adhesion. After
washing 200 μL of re-calcified human plasma was added
to the monocytes. Clotting time was measured in dupli-
cate by using a coagulometer (Amelung; Lemgo, Ger-
many). In some experiments monocytes were pre-
treated with signal transduction inhibitors such as SB
202190 that inhibits p38 MAPK, U0126 which inhibits
MEK1 and MEK2. Furthermore NF-kB was inhibited by
Figure 5 Inhibition of MMP-9 decreases the fibrinogen-
triggered pro-coagulant activation of human monocytes.
Monocytes were pre-treated with specific inhibitors of matrix
metalloproteases (MMP)-1, -3, -8, -9 and -13, and exposed to
fibrinogen. Then coagulation experiments were performed. The
inhibitor of MMP-9 increased the time to clot formation to 355 ±
23.4 sec which was about the same for un-treated cells. Other MMP
inhibitors did not interfere with fibrinogen-initiated clot formation.
Results are given as mean ± SEM, n = 3. MMP-9: p < 0.05.
Figure 6 Fibrinogen-treatment induces MMP-9 secretion from human monocytes. Human monocytes were exposed to different
concentrations of fibrinogen and MMP-9 levels were measured in the supernatants (A) and intra-cellularly (B). In the supernatants of the
fibrinogen-treated cells, MMP-9 levels were 15 times higher than in un-treated monocytes were measured. Intracellular MMP-9 levels did not
increase twice the concentration of untreated cells. Results are given as mean ± SEM, n = 3.*: p < 0.05.
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the addition of JNK Inhibitor II. The concentration used
was 3 × IC50 for each inhibitor. After washing fibrino-
gen was added and the cells were incubated with fibri-
nogen for another 4 hours.
For mouse studies animals were injected with 20 mg
of fibrinogen. Four hours after injection, blood was col-
lected by terminal cardiac puncture and the red blood
cells were removed by lysis. Again, clotting time was
measured by the method described above.
Determination of MMP levels
Matrix metallo proteases (MMPs) were measured either
in monocyte supernatants or after treating monocytes
with lysing buffer (intra-cellular levels). Monocytes were
stimulated with fibrinogen for 4 h then the supernatans
were collected and subjected to commercially available
proMMP-1 and MMP-9 ELISA assays. After collecting
the supernatants, cells were lysed and after spinning
down the cell detritus, intra-cellular MMP-levels were
measured as well by the same method. section.
In vivo monocyte migration assay
Six to 8 week old female CD-1 mice were given 20 mg
of fibrinogen i.p. 4 days after the injection mice were
sacrificed by CO2-inhalation and peritoneal lavage was
performed with 10 mL of lukewarm 0.9% sodium chlor-
ide. Cells were counted in a Neubauer chamber. Periph-
eral leukocytes were counted in a Neubauer chamber
after the lysis of red blood cells.
Statistics
Results are given as mean and standard error of the mean.
Statistics were calculated after Kruskal Wallis and Mann
Whitney U tests using StatView (Abacus, Berkeley, CA).
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